Hong Kong Biotech Stock News

Why Chery Automobile Is Drawing Investor Attention Now Chery Automobile (SEHK:9973) has caught investor interest recently, with the share price around HK$28.68 and short term returns mixed across the past week, month, and past 3 months. See our latest analysis for Chery Automobile. Stepping back from the daily moves, Chery Automobile’s share price return has been slightly positive over the past week but softer over the past quarter and year to date. This hints that earlier momentum has cooled...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hengan International Group fair value estimate is HK$34.85...

If you are wondering whether Tencent Holdings is attractively priced today or already reflects most of its potential, this article will walk you through how its current share price stacks up against several valuation checks. Tencent's share price last closed at HK$532.0, with a 2.8% decline over 7 days, a 13.8% decline over 30 days and a 14.6% decline year to date, while the 1 year return sits at 13.0% and the 3 year return at 45.8%, compared to a 19.6% decline over 5 years. Recent headlines...

As global markets navigate the complexities of AI disruption and economic shifts, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 experiencing notable gains. In this environment, identifying undervalued stocks requires a keen eye for companies that demonstrate strong fundamentals and potential for growth amidst changing market conditions.

Lenovo Group recently reported third-quarter 2025/26 results showing record sales of US$22,204.33 million, alongside lower quarterly net income of US$545.54 million, while nine‑month profits edged higher year on year to US$1.39 billion. At the same time, Lenovo highlighted rapid growth in AI‑related revenue, restructured its Infrastructure Solutions Group for long-term AI opportunities, and launched new ThinkSmart–Huddly meeting solutions to deepen its presence in AI‑enabled...

The Meitu, Inc. ( HKG:1357 ) share price has fared very poorly over the last month, falling by a substantial 30...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

China National Building Material Company Limited ( HKG:3323 ) shares have had a really impressive month, gaining 27...

The Honworld Group Limited ( HKG:2226 ) share price has fared very poorly over the last month, falling by a substantial...

The Bank of East Asia, Limited ( HKG:23 ) is reducing its dividend from last year's comparable payment to HK$0.22 on...

To the annoyance of some shareholders, TI Cloud Inc. ( HKG:2167 ) shares are down a considerable 28% in the last month...

Despite an already strong run, TBK & Sons Holdings Limited ( HKG:1960 ) shares have been powering on, with a gain of...

With a price-to-earnings (or "P/E") ratio of 22.7x Kingsoft Corporation Limited ( HKG:3888 ) may be sending very...

Sun.King Technology Group (HKG:580) has had a rough three months with its share price down 11%. It is possible that the...

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...

Despite an already strong run, China Gingko Education Group Company Limited ( HKG:1851 ) shares have been powering on...

As global markets navigate concerns over AI disruption and fluctuating economic indicators, Asia's stock markets have shown resilience, with Japan experiencing significant gains following political developments and China maintaining steady growth despite deflationary pressures. In this climate of uncertainty, investors often look for companies with strong insider ownership as it can signal confidence in the company's prospects by those who know it best.

The Asian markets have been a focal point for investors as they navigate the complexities of global economic shifts, with China's consumer inflation easing and Japan's stock markets experiencing gains. For those interested in exploring beyond the well-trodden paths of large-cap stocks, penny stocks—despite their somewhat outdated moniker—continue to present intriguing opportunities. These smaller or newer companies can offer significant value, especially when they possess strong financial...

Why InSilico Medicine Cayman TopCo is on investors’ radar InSilico Medicine Cayman TopCo (SEHK:3696) has recently caught attention after a strong share price move, including an 18.3% return over the past week and 33.3% over the past month. See our latest analysis for InSilico Medicine Cayman TopCo. The recent jump in InSilico Medicine Cayman TopCo’s share price, with a 7 day share price return of 18.3% and 30 day share price return of 33.3%, sits within a much stronger year to date share...

China Conch Venture Holdings (SEHK:586) has issued its first tranche of 2026 green medium term notes, raising RMB1.235 billion at a 1.9% coupon. The notes are rated AAA by China Lianhe Credit Rating. See our latest analysis for China Conch Venture Holdings. The green note issue comes after a strong run in the shares, with a 1 month share price return of 25.80% and a year to date share price return of 26.46%. The 1 year total shareholder return of 91.44% contrasts with weaker 3 and 5 year...

What Cirrus Aircraft’s G3 Vision Jet Launch Means For Shareholders Cirrus Aircraft (SEHK:2507) has just begun delivering its Generation 3 Vision Jet, featuring an expanded seven seat layout, refreshed interior materials, and updated avionics including ATC Datalink and other flight deck refinements. This product launch gives investors a fresh reference point to consider Cirrus Aircraft’s position in personal aviation, in the context of its existing revenue of HK$1,316.235 million and net...

Why Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline. See our latest analysis for Suzhou Ribo Life Science. The latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...

Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions. See our latest analysis for Akeso. Investors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...

Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China. See our latest analysis for Alphamab Oncology. The JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5...